Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9826519 | 0.75 | ULK1 (0.41) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL2937272 | 0.75 | CA12 (0.47) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL256714 | 0.75 | CNR2 (0.44) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL69393 | 0.75 | NR4A2 (0.44) | CNR2ALDH1A1KDM4EGAATSHR | |
| SCHEMBL24840712 | 0.73 | CNR2 (0.43) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL30478971 | 0.73 | CNR2 (0.43) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL13729391 | 0.73 | CNR2 (0.43) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL21366811 | 0.73 | CNR2 (0.43) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL27969448 | 0.73 | ALDH1A1 (0.46) | CNR2ALDH1A1KDM4EGAAHTT | |
| SCHEMBL257478 | 0.73 | CNR2 (0.43) | CNR2ALDH1A1KDM4EGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119365460-A | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases | 尚医治疗有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2024-10-31 | — | — | US | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | CNR2 3541/4885ALDH1A1 2587/4885KDM4E 4343/4885 |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | CNR2 285/4885ALDH1A1 538/4885KDM4E 2413/4885 |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, HRAS, NRAS | CNR2 3541/4885ALDH1A1 2587/4885KDM4E 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.